E3S Web Conf.
Volume 245, 20212021 5th International Conference on Advances in Energy, Environment and Chemical Science (AEECS 2021)
|Number of page(s)||4|
|Section||Chemical Performance Research and Chemical Industry Technology Research and Development|
|Published online||24 March 2021|
Targeting Cystic Fibrosis: A review from Pathogenesis to Innovative Clinical Strategies
Woodward Academy, College Park, Georgia, 30337, the United State ;
* Corresponding author’s e-mail: firstname.lastname@example.org
Cystic fibrosis is a hereditary disease caused by mutation in cystic fibrosis transmembrane conductance regulator (CFTR) gene, which controls CFTR proteins. Many are or have been threatened by this rare but life-threating disease, therefore, more attention should be paid to better solve this public health issue. Here we provide a thorough review about cystic fibrosis in the aspects of disease pathogenesis, clinical manifestation as well as clinical therapeutics to achieve a deeper understanding of this disease. Among the demand of innovative clinical strategies, appearance of the combination drug trikafta is a promising sign of better dealing with cystic fibrosis.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.